GeoVax (United States)

GeoVax (United States)

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for GeoVax (United States), United States, covering academic research published from 2007 to 2023. Read More.


Open Access Percentage

84%


Total
Publications

50


Total Open
Publications

42


Total
Citations

1.1K


Open Access
Percentage

84%


Total
Publications

50


Total Open
Publications

42


Total
Citations

1.1K

Wikipedia

Website

download

Breakdown

10% 64% 10% 16%

Publisher Open

10%

Both

64%

Other Platform Open

10%

Closed

16%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
20072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

00.511.522.533.544.555.566.57Total Publications
20072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

51%OA Journal

OA Journal 51%

19

Hybrid 11%

4

No Guarantees 38%

14

Other Platform Open

Domain 100%

37

Public 16%

6

Institution 8%

3

Preprint 0%

0

Other Internet 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
37
Europe PMC
Domain
31
Semantic Scholar
Public
6
University of Massachusetts Medical School - eScholarship@UMMS
Institution
2
University of North Carolina at Chapel Hill - Carolina Digital Repository
Institution
1
Harvard University - Digital Access to Scholarship at Harvard (DASH)
Institution
1
Figshare
Public
1
1 / 1

Data updated 13 May 2024

Share

Share

Share